Reimbursed Care Access in Monaco

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (intranasal Spravato) holds a centralized EU marketing authorisation (European Commission / EMA) for treatment‑resistant major depressive disorder and related acute indications, authorised 18 December 2019 by the EMA. #.

Because Monaco operates a state social insurance (Caisses Sociales de Monaco) and exercises ministerial control over which medicines are placed on local reimbursement/dispensing lists, medicines authorised at the European/international level are not automatically reimbursed in the Principality — national (ministerial) listing and specific inclusion on Monaco reimbursement/ministerial arrêté are required for full public reimbursement via the Caisses Sociales. See the Government of Monaco Ministry of Health overview (structure includes the State Medical Benefits Office / Caisses Sociales). #.

Practical implication for patients: esketamine’s EMA authorisation makes it clinically approvable by psychiatrists in EU/EEA‑authorised jurisdictions; in Monaco it can be prescribed where local regulatory/market arrangements permit but routine public reimbursement requires ministerial inclusion on the reimbursable medicines list (an arrêté/Journal officiel procedure in Monaco governs which medicines and which prescribing authorities are covered). The list and formal reimbursement rules in Monaco are managed by the State Medical Benefits Office and set by ministerial arrêté under Monaco’s law on medicines. #.

Operational notes: where esketamine is provided, it must be administered under supervised clinical conditions consistent with the EMA/REM S safety requirements (clinic observation, blood‑pressure monitoring, documentation of prior antidepressant failures). Reimbursement or patient cost exposure in Monaco will depend on whether Caisses Sociales has formally adopted the product into its reimbursable medicines list and on any supplementary private insurance (mutuelle) coverage; absent an explicit Monaco ministerial reimbursement decision, treatment is likely to be available only through private payment or hospital purchase. # # #.

Racemic ketamine (intravenous or intramuscular) is a licensed anaesthetic agent internationally but remains an off‑label psychiatric treatment for depression and other mental‑health indications across Europe; its psychiatric use is practiced in specialised clinics and is commonly billed privately because formal reimbursement for ketamine as a psychiatric therapy depends on national pharmaco‑regulatory listings and specific insurer policy. Systematic reviews document robust, rapid, but often transient antidepressant and anti‑suicidal effects and widespread off‑label adoption in Europe, while emphasising the need for controlled delivery and pharmacovigilance. #.

In Monaco the same ministerial framework (State Medical Benefits Office / Caisses Sociales) determines public reimbursement and the ministerial arrêté / law on medicines governs which products and indications are covered; racemic ketamine used for psychiatric indications would normally be provided as an off‑label clinical intervention and is therefore most often delivered in private clinics or as hospital‑administered treatment with variable reimbursement depending on prior authorisation and whether the specific use has been listed by the State medical authorities. There is no evidence of a specific, publicly reimbursed ketamine‑for‑depression program established by Monaco’s social insurance as of the latest available sources. # #.

Operational considerations: clinicians using ketamine for psychiatric indications should follow established protocols, document prior treatment failures (if claiming medical necessity), and seek prior authorisation from the Caisses Sociales when attempting to obtain public reimbursement; absent explicit ministerial reimbursement, care is commonly self‑pay or covered by private supplemental insurance in comparable European systems. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.